
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development